After asthma: redefining airways diseases

Ian D. Pavord; Richard Beasley; Alvar Agusti; Gary P. Anderson; Elisabeth Bel; Guy Brusselle; Paul Cullinan; Adnan Custovic; Francine M. Ducharme; John V. Fahy; Urs Frey; Peter Gibson; Liam G. Heaney; Patrick G. Holt; Marc Humbert; Clare M. Lloyd; Guy Marks; Fernando D. Martinez; Peter D. Sly; Erika von Mutius; Sally Wenzel; Heather J. Zar; Andy Bush

doi:10.1016/S0140-6736(17)30879-6

After asthma: redefining airways diseases

Ian D. Pavord, Richard Beasley, Alvar Agusti, Gary P. Anderson, Elisabeth Bel, Guy Brusselle, Paul Cullinan, Adnan Custovic, Francine M. Ducharme, John V. Fahy, Urs Frey, Peter Gibson, Liam G. Heaney, Patrick G. Holt, Marc Humbert, Clare M. Lloyd, Guy Marks, Fernando D. Martinez, Peter D. Sly, Erika von MutiusSally Wenzel, Heather J. Zar, Andy Bush

Research output: Contribution to journal › Review article › peer-review

571 Scopus citations

Original language	English (US)
Pages (from-to)	350-400
Number of pages	51
Journal	The Lancet
Volume	391
Issue number	10118
DOIs	https://doi.org/10.1016/S0140-6736(17)30879-6
State	Published - Jan 27 2018

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(17)30879-6

Cite this

Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., Frey, U., Gibson, P., Heaney, L. G., Holt, P. G., Humbert, M., Lloyd, C. M., Marks, G., Martinez, F. D., Sly, P. D., ... Bush, A. (2018). After asthma: redefining airways diseases. The Lancet, 391(10118), 350-400. https://doi.org/10.1016/S0140-6736(17)30879-6

Pavord, ID, Beasley, R, Agusti, A, Anderson, GP, Bel, E, Brusselle, G, Cullinan, P, Custovic, A, Ducharme, FM, Fahy, JV, Frey, U, Gibson, P, Heaney, LG, Holt, PG, Humbert, M, Lloyd, CM, Marks, G, Martinez, FD, Sly, PD, von Mutius, E, Wenzel, S, Zar, HJ & Bush, A 2018, 'After asthma: redefining airways diseases', The Lancet, vol. 391, no. 10118, pp. 350-400. https://doi.org/10.1016/S0140-6736(17)30879-6

@article{03f31c004fec49f9a3a7e23234372a96,

title = "After asthma: redefining airways diseases",

author = "Pavord, {Ian D.} and Richard Beasley and Alvar Agusti and Anderson, {Gary P.} and Elisabeth Bel and Guy Brusselle and Paul Cullinan and Adnan Custovic and Ducharme, {Francine M.} and Fahy, {John V.} and Urs Frey and Peter Gibson and Heaney, {Liam G.} and Holt, {Patrick G.} and Marc Humbert and Lloyd, {Clare M.} and Guy Marks and Martinez, {Fernando D.} and Sly, {Peter D.} and {von Mutius}, Erika and Sally Wenzel and Zar, {Heather J.} and Andy Bush",

note = "Funding Information: One difficulty in these and associated trials is determining risk because the positive predictive value of many available indices are poor, although negative prediction is very good. 76,257,258 These predictive indices are based on the crudest markers, which is a recurring theme because the respiratory community has failed to utilise modern omics technology to establish predictive biomarkers, although some progress has been achieved recently. 259 The first major initiative in this regard is targeted prevention of allergic sensitisation in high-risk infants by immune tolerance induction using prophylactic allergen-specific sublingual immunotherapy, with the aim of reducing ensuing asthma development by ages 5–6 years. This trial was downgraded to pilot status after recruitment of only 50 children, enabling subsequent collection of safety data only. 260 However, a conceptually identical trial 261 funded by the National Institute of Allergy and Infectious Diseases, which aimed to prevent allergen-specific sensitisation to food allergen by oral administration of tolerogenic doses of allergen, has successfully achieved its primary endpoints. Additionally, a smaller sublingual tolerance induction trial 262 in the UK funded by the Medical Research Council that targeted prevention of sensitisation to aeroallergens has achieved partial success. This approach clearly shows promise and should be systematically followed up. Encouragingly, several such studies are at the planning stage. ",

year = "2018",

month = jan,

day = "27",

doi = "10.1016/S0140-6736(17)30879-6",

language = "English (US)",

volume = "391",

pages = "350--400",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10118",

}

TY - JOUR

T1 - After asthma

T2 - redefining airways diseases

AU - Pavord, Ian D.

AU - Beasley, Richard

AU - Agusti, Alvar

AU - Anderson, Gary P.

AU - Bel, Elisabeth

AU - Brusselle, Guy

AU - Cullinan, Paul

AU - Custovic, Adnan

AU - Ducharme, Francine M.

AU - Fahy, John V.

AU - Frey, Urs

AU - Gibson, Peter

AU - Heaney, Liam G.

AU - Holt, Patrick G.

AU - Humbert, Marc

AU - Lloyd, Clare M.

AU - Marks, Guy

AU - Martinez, Fernando D.

AU - Sly, Peter D.

AU - von Mutius, Erika

AU - Wenzel, Sally

AU - Zar, Heather J.

AU - Bush, Andy

N1 - Funding Information: One difficulty in these and associated trials is determining risk because the positive predictive value of many available indices are poor, although negative prediction is very good. 76,257,258 These predictive indices are based on the crudest markers, which is a recurring theme because the respiratory community has failed to utilise modern omics technology to establish predictive biomarkers, although some progress has been achieved recently. 259 The first major initiative in this regard is targeted prevention of allergic sensitisation in high-risk infants by immune tolerance induction using prophylactic allergen-specific sublingual immunotherapy, with the aim of reducing ensuing asthma development by ages 5–6 years. This trial was downgraded to pilot status after recruitment of only 50 children, enabling subsequent collection of safety data only. 260 However, a conceptually identical trial 261 funded by the National Institute of Allergy and Infectious Diseases, which aimed to prevent allergen-specific sensitisation to food allergen by oral administration of tolerogenic doses of allergen, has successfully achieved its primary endpoints. Additionally, a smaller sublingual tolerance induction trial 262 in the UK funded by the Medical Research Council that targeted prevention of sensitisation to aeroallergens has achieved partial success. This approach clearly shows promise and should be systematically followed up. Encouragingly, several such studies are at the planning stage.

PY - 2018/1/27

Y1 - 2018/1/27

UR - http://www.scopus.com/inward/record.url?scp=85029208732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029208732&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(17)30879-6

DO - 10.1016/S0140-6736(17)30879-6

M3 - Review article

C2 - 28911920

AN - SCOPUS:85029208732

VL - 391

SP - 350

EP - 400

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10118

ER -

After asthma: redefining airways diseases

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this